HER2‐targeted therapeutics, including trastuzumab and T‐DXd, have revolutionized the treatment of HER2‐positive tumors.[27] In the current study, we designed, synthesized, and characterized a novel formulation composed of trastuzumab‐decorated immunoliposomes (HER2‐TNM A‐ILs) that exhibited remarkable efficacy in suppressing KPL‐4 tumor growth in mice treated with a single dose without systemic toxicity (Figures 5 and 6). This evidence concerns the gene ERBB2 and neoplasm.